4//SEC Filing
Lee Gary K. 4
Accession 0001415889-25-021692
CIK 0001806952other
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 9:08 PM ET
Size
8.0 KB
Accession
0001415889-25-021692
Insider Transaction Report
Form 4
Lee Gary K.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-08-11$10.53/sh−131$1,379→ 9,093 total - Sale
Common Stock
2025-08-12$10.34/sh−136$1,406→ 8,957 total
Footnotes (7)
- [F1]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F2]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F3]Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F4]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
- [F5]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F6]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F7]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
Documents
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001907345
Filing Metadata
- Form type
- 4
- Filed
- Aug 12, 8:00 PM ET
- Accepted
- Aug 13, 9:08 PM ET
- Size
- 8.0 KB